🎉 M&A multiples are live!
Check it out!

Chengdu Easton Valuation Multiples

Discover revenue and EBITDA valuation multiples for Chengdu Easton and similar public comparables like Armata Pharmaceuticals, Vivoryon Therapeutics, and Pharming.

Chengdu Easton Overview

About Chengdu Easton

Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.


Founded

2009

HQ

China
Employees

n/a

Website

eastonpharma.cn

Financials

LTM Revenue $201M

Last FY EBITDA $48.5M

EV

$1.3B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Chengdu Easton Financials

As of December 2025, Chengdu Easton reported last 12-month revenue of $201M.

In the same period, Chengdu Easton generated $153M in LTM gross profit and $39.0M in net income.

See Chengdu Easton valuation multiples based on analyst estimates

Chengdu Easton P&L

In the most recent fiscal year, Chengdu Easton reported revenue of $193M and EBITDA of $48.5M.

Chengdu Easton expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Chengdu Easton valuation multiples based on analyst estimates
LTM NTM Last FY FY 2026 FY 2027 FY 2028
Revenue $201M XXX $193M XXX XXX XXX
Gross Profit $153M XXX $145M XXX XXX XXX
Gross Margin 76% XXX 75% XXX XXX XXX
EBITDA n/a XXX $48.5M XXX XXX XXX
EBITDA Margin n/a XXX 25% XXX XXX XXX
EBIT $40.4M XXX $31.7M XXX XXX XXX
EBIT Margin 20% XXX 16% XXX XXX XXX
Net Profit $39.0M XXX $34.0M XXX XXX XXX
Net Margin 19% XXX 18% XXX XXX XXX
Net Debt XXX XXX n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Chengdu Easton Stock Performance

Chengdu Easton has current market cap of CNY 10.4B (or $1.5B), and EV of CNY 9.0B (or $1.3B).

Market Cap Evolution

Chengdu Easton Stock Data

As of January 16, 2026, Chengdu Easton's stock price is CNY 59 (or $8).

See Chengdu Easton trading valuation data
EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.3B $1.5B XXX XXX XXX XXX $0.22

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Chengdu Easton Valuation Multiples

Chengdu Easton's trades at 6.4x EV/Revenue multiple, and 26.5x EV/EBITDA.

See valuation multiples for Chengdu Easton and 15K+ public comps

Chengdu Easton Financial Valuation Multiples

As of January 16, 2026, Chengdu Easton has market cap of $1.5B and EV of $1.3B.

Equity research analysts estimate Chengdu Easton's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

Chengdu Easton has a P/E ratio of 38.2x.

LTM NTM Last FY FY 2026 FY 2027 FY 2028
Market cap (current) $1.5B XXX $1.5B XXX XXX XXX
EV (current) $1.3B XXX $1.3B XXX XXX XXX
EV/Revenue 6.4x XXX 6.4x XXX XXX XXX
EV/EBITDA n/a XXX 26.5x XXX XXX XXX
EV/EBIT 31.7x XXX 31.7x XXX XXX XXX
EV/Gross Profit 8.4x XXX n/a XXX XXX XXX
P/E 38.2x XXX 38.2x XXX XXX XXX
EV/FCF n/a XXX 61.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Chengdu Easton Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Chengdu Easton Margins & Growth Rates

Chengdu Easton's last 12 month revenue growth is 18%

Chengdu Easton's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Chengdu Easton's rule of 40 is 46% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Chengdu Easton's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Chengdu Easton and other 15K+ public comps

Chengdu Easton Operational Valuation Multiples

LTM NTM Last FY FY 2026 FY 2027 FY 2028
Revenue Growth 18% XXX 19% XXX XXX XXX
EBITDA Margin n/a XXX n/a XXX XXX XXX
EBITDA Growth n/a XXX n/a XXX XXX XXX
Rule of 40 46% XXX n/a XXX XXX XXX
Bessemer Rule of X XXX XXX n/a XXX XXX XXX
Revenue per Employee XXX XXX n/a XXX XXX XXX
Opex per Employee XXX XXX n/a XXX XXX XXX
S&M Expenses to Revenue XXX XXX 28% XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX 20% XXX XXX XXX
Opex to Revenue XXX XXX 59% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Chengdu Easton Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Small Molecules comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
Armata Pharmaceuticals XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Chengdu Easton M&A and Investment Activity

Chengdu Easton acquired  XXX companies to date.

Last acquisition by Chengdu Easton was  XXXXXXXX, XXXXX XXXXX XXXXXX . Chengdu Easton acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Chengdu Easton

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.

Start Free Trial

About Chengdu Easton

When was Chengdu Easton founded? Chengdu Easton was founded in 2009.
Where is Chengdu Easton headquartered? Chengdu Easton is headquartered in China.
Is Chengdu Easton publicy listed? Yes, Chengdu Easton is a public company listed on SHG.
What is the stock symbol of Chengdu Easton? Chengdu Easton trades under 688513 ticker.
When did Chengdu Easton go public? Chengdu Easton went public in 2020.
Who are competitors of Chengdu Easton? Similar companies to Chengdu Easton include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of Chengdu Easton? Chengdu Easton's current market cap is $1.5B
What is the current revenue of Chengdu Easton? Chengdu Easton's last 12 months revenue is $201M.
What is the current revenue growth of Chengdu Easton? Chengdu Easton revenue growth (NTM/LTM) is 18%.
What is the current EV/Revenue multiple of Chengdu Easton? Current revenue multiple of Chengdu Easton is 6.4x.
Is Chengdu Easton profitable? Yes, Chengdu Easton is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.